Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY2452473 · OPK-88004

Small molecule · Modulator of androgen receptor (AR) · developed by OPKO Health

Phase 2 Most advanced trial (none active)
OPK Developer
1 Registered trials

What is LY2452473?

LY2452473 is an orally bioavailable selective androgen receptor modulator (SARM). It binds the androgen receptor, acting as an agonist in skeletal muscle, bone and the penis and as an antagonist in the prostate. It is studied in benign prostatic hyperplasia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OPK-88004
Drug type
Small molecule
Targets
androgen receptor (AR)
Mechanism
Modulator of androgen receptor (AR)
Pathways
androgen receptor signaling, AR-mediated cellular proliferation
Therapy area
Renal & urology
Developer
OPKO Health, Inc. (OPK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
XKW9MYF94Y

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03297398 Phase 2 Benign Prostatic Hyperplasia Terminated OPK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Benign Prostatic Hyperplasia

Other drugs acting on AR

More from OPKO Health

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.

Follow OPK, the company behind LY2452473

See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OPK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.